Parotid Tumors Market
Information: By Type (Pleomorphic Adenoma) By Treatment (Removal Of Lymph Node,
Radiation Therapy, Chemotherapy) By Diagnosis (Ct Scan, Ultrasound,
Sialography) And End Users (Hospitals, Specialty Centers) – Global Forecast
Till 2023
Market Scenario
The parotid glands are prone to
parotitis, injury, fibrous reaction, parotid tumors, and cancers. Parotid tumors are abnormal growth within the salivary gland and can be both cancerous
as well as non-cancerous. They are caused by liver cirrhosis, abdominal
surgery, salivary gland infections, dehydration, salivary duct stones, and
metastasis of cancer.
Drivers and Constraints Affecting
the Parotid Tumors Market
The human body consists of two
parotid glands on either side of the face. The growth of the tumors are generally
slow and benign, but in seldom cases, the growth can be malignant. Increasing
consumption of alcohol, growing liver cirrhosis, and increasing prevalence of
cancer are some of the major factors driving the market over the assessment
period. With the growing demand for advanced technologies, government support
and initiatives, and the presence of growing market players, the market for
parotid tumor is anticipated to expand at a staggering rate over the review
period. For instance, according to Cancer Research U.K., over 14.1 million
cancer cases were diagnosed in the year 2014. According to the national cancer
institute, over 14.5 million cancer cases went undiagnosed in the year 2014.
Such statistics have pushed the number of cancer cases and are likely to spur
the market growth over the review period.
However, complications such as
facial nerve paralysis, hemorrhage or hematoma, infection, cosmetic deformity,
and others arising after the required treatment are supposed to hinder the
growth of the global parotid tumor market.
Global Parotid Tumor Market:
Segmental Analysis
Globally, the parotid tumor
market has been segmented on the basis of treatment, type, diagnosis, and
end-users.
The market has been segmented
into Warthin's tumor, pleomorphic adenoma, pleomorphic adenoma, and
cancerous/malignant tumor based on type. In most cases, parotid tumors are
benign, but in seldom cases the tumors are cancerous. Pleomorphic Adenoma is
the most common type of benign parotid tumor which is also termed as benign mixed
tumor. A pleomorphic adenoma might grow if not removed or left untreated.
The market has been segmented
into removal of lymph node, parotidectomy, radiation therapy, reconstructive
surgery, and chemotherapy based on treatment. Surgical procedures require complete
or partial removal of parotid gland; a common procedure being parotidectomy.
The market has been segmented
into X-ray, CT scan, MRI, ultrasound, fine needle aspiration cytology (FNAC),
sialography, and others based on diagnosis.
The market has also been
segmented into specialty centers, hospitals, and research centers based on
end-users.
North America to Dominate the
Market
Geographically, the market for
parotid tumor has been spanned across North America, Europe, Asia Pacific, and
the Middle East and Africa. Among these, the North American region is predicted
to be the growing market in the American region. Growing consumption of alcohol
among the crowd coupled with the increasing number of cancer is anticipated to
drive the market in this region. Moreover, with the rising expenditure on
healthcare the market is expected to expand over the assessment period. For
instance, as per National Institute on alcohol abuse and alcoholism, around
26.9 % individuals above 18 years of age consume alcohol. According to Agency
for Healthcare Research and Quality, over USD 80.2 billion was spent in
treating cancer.
The European region is projected
to hold a noticeable share and is expected to be the second largest market
after North America. Due to the availability of advanced treatment coupled with
skilled medical professionals and growing need for healthcare infrastructure,
the market in this region is expected to witness a healthy growth.
On the other hand, Asia Pacific
is anticipated to be the fastest growing market over the review period owing to
the growing prevalence of chronic diseases. India is one of the fastest regions
due to increasing population. Availability of new treatment methods and growing
concern about health is expected to drive the market in this region.
The Middle East and Africa are
estimated to show the least growth rate due to lack of awareness and limited
access to treatment facilities. The United Arab Emirates is the largest market
in the Middle East owing to the availability of specialty care centers and
development of healthcare industry.
For More Information Visit @ https://www.marketresearchfuture.com/reports/parotid-tumors-market-5678
Industry News
Atlantic Health System’s new
Atlantic HPV Center will begin a study to determine whether an innovative
combination of immuno-oncology treatments is safe, shows preliminary efficacy
and provokes an anticancer immune system response in patients with recurrent or
metastatic human papillomavirus (HPV) associated head and neck squamous cancer.
Recent evidence proves that several cases of squamous head and neck cancer
which was previously caused due to smoking might now be caused by sexually
transmitted HPV.
Competition Analysis
The prominent players operating
the market for parotid tumors are Novartis AG, Pfizer Inc., Bristol-Myers
Squibb, Janssen Global Services LLC, Bayer AG, Hoffmann-La Roche Ltd, Merck
& Co. Inc., Eli Lilly & Co, and others.
No comments:
Post a Comment